Articles tagged with Cancer Medication
The FDA-approved drug sotorasib has been shown to reduce tumor size and improve survival among patients with non-small-cell lung cancer caused by a specific DNA mutation. The study involved 126 patients who showed significant responses to the treatment, including 34% achieving partial response and 3% complete response.
A new drug, sotorasib, has shown significant benefit in treating non-small-cell lung cancer patients with a specific KRAS mutation. The study found that 37.1% of patients experienced tumor shrinkage and 82% saw slowing of tumor growth.
Researchers found that nivolumab significantly reduced bladder cancer recurrence after surgery in high-risk patients. Disease-free survival was 21 months for nivolumab recipients compared to 10.9 months for placebo recipients.
A national survey of breast cancer patients and oncologists reveals that nearly three-quarters of patients use complementary medicine during treatment, yet doctors often fail to discuss integrative health with patients. Patients report finding hope and improving quality of life through these therapies.
A new study published in Nature reveals that a commonly used psychiatric drug can boost the fitness of healthy gut stem cells, making them more resistant to cancer. A clinical trial is now underway to investigate whether lithium can prevent bowel cancer in individuals with familial adenomatous polyposis (FAP).
A global review found that Opioid Agonist Therapy (OAT) is associated with lower risk of multiple causes of death among people with opioid dependence. OAT was linked to reduced overdose-related, suicide, alcohol-related, cancer, and cardiovascular-related mortality.
Researchers from SWOG presented results on several studies, including S1216 and S1404, which showed promising findings for patients with prostate and melanoma cancers. Additionally, secondary analyses from S0809 and S1200 revealed benefits of adjuvant chemoradiation and acupuncture for certain cancer types.
Australian scientists have discovered a new and effective way to treat high-risk blood cancer in children. A combination of ruxolitinib with commonly used anticancer drugs showed enhanced treatment efficacy in two out of three patient-derived xenograft models, achieving long-term suppression of leukaemia growth.
Researchers found that certain drugs can alter cell mechanical properties without reducing effectiveness, allowing for lower doses. The study used atomic force microscopy to measure cell rigidity and actin filament activity, enabling precise determination of optimal drug concentrations.
University of Virginia researchers have developed a new computational method to map the folding patterns of chromosomes in three dimensions. This will help scientists understand the genetic cause of cancer and advance other areas of medical research.
Even among insured individuals, up to 10% of cancer survivors delayed follow-up care due to financial constraints. Financial stress and anxiety hinder timely survivorship care, particularly among vulnerable populations such as racial minorities, women, and those with lower incomes.
MUSC researchers develop peptide siRNA carriers that improve gene silencing and deliver siRNA into cancer cells. The modified carriers, such as RD3AD, use filopodia entry to efficiently deliver the therapeutic molecules.
Researchers found that obesity-associated metabolic factors activate myeloid-derived suppressor cells, which can enhance cancer risk. Additionally, a prospective cohort study revealed meaningful differences in cancer risk by race and sex among obese adults.
Researchers at UC Riverside developed an implantable drug delivery system using piezoelectric nanofibers that can release therapeutic molecules on demand. The system offers robust control over release rate and precision in administering drug molecules, making it suitable for treating chronic diseases.
A dental school researcher has received FDA approval to begin clinical trials for a new cancer therapy using a protein found in an oral bacterium. The treatment, Leukothera, rapidly kills cancer cells without compromising the immune system, offering a potential alternative to existing treatments.
Researchers have developed a prognostic and therapeutic epigenetic biomarker for PDAC patients, predicting which are likely to benefit from traditional chemotherapy. The technology addresses a pressing clinical need by introducing the first ever epigenetic precision medicine approach to pancreatic cancer.
Decitabine, used to treat blood cancers like MDS and AML, works by activating endogenous retroviruses that induce an immune response. The study found two key gene sequences involved in this process, Staufen1 and TINCR, whose expression levels determine a patient's response to the drug.
Researchers at Dana-Farber Cancer Institute presented numerous studies on various types of cancer, including kidney cancer, melanoma, and lung cancer. The studies focused on innovative treatments, diagnostic advances, and patient outcomes.
Researchers developed two experimental drug approaches targeting cancer cell metabolism, showing promise in treating highly aggressive pediatric brain cancer. The treatments extended survival and enhanced effectiveness of standard chemotherapies in patients with MYC-amplified medulloblastoma.
A new study led by UT Southwestern scientists shows that an experimental drug, avasopasem manganese (AVA), enhances radiation's capacity to kill tumors while protecting healthy tissue from collateral damage. The findings could provide a much-needed boost to radiation treatments used against various tumor types.
The GEM ExTra test uses whole exome sequencing and RNA sequencing to detect actionable mutations in patients with advanced solid tumors. It has been validated through clinical utilization and provides clinically actionable information to guide patient management decisions.
In a Phase I trial, IACS-6274 demonstrated successful target inhibition and early signs of anti-tumor activity in 60% of evaluable patients. Durable disease stabilization was observed in six patients with biomarker-defined advanced cancers.
A fixed-dose combination of nivolumab and relatlimab demonstrated a statistically significant benefit over anti-PD-1 monotherapy in metastatic melanoma. The study found that patients treated with the combination therapy had a median progression-free survival of 10.1 months, compared to 4.6 months for those treated with nivolumab alone.
A new study suggests that cardioprotective drugs during adjuvant breast cancer therapy may not be necessary for most patients, especially those at low risk of heart disease. The research found no significant differences in heart function between patients who received these medications and placebos.
University of Alberta scientists have identified Toll-like receptor 4 as a potential target for preventing permanent hearing loss caused by the chemotherapy drug cisplatin. By inhibiting this receptor, they may be able to eliminate toxic side effects from the drug that cause hearing loss in childhood cancer survivors.
Researchers found that lasofoxifene outperformed fulvestrant in reducing primary tumor growth and preventing metastasis in the lung, liver, bone, and brain. Additionally, lasofoxifene prevents unwanted side effects, including menopausal-like symptoms.
Researchers find a way to target both pancreatic cancer cells and the scar tissue surrounding them, reducing tumor growth and spreading. A new clinical trial aims to test this approach with an existing anti-arthritis drug, potentially improving treatment response and patient survival.
A new four-drug combination treatment has shown promise in preventing cancer metastasis without triggering drug resistance. The treatment targets multiple pathways to suppress cancer cell spread and may help identify patients who would benefit from such therapy.
A phase II study by Penn Medicine shows rucaparib helped control cancer growth in patients with BRCA or PALB2 genetic mutations. The results support the use of rucaparib as a maintenance therapy for pancreatic cancer patients, offering a safe and effective alternative to chemotherapy.
A new study suggests that CDK4 and CDK6 inhibitors can improve immune-cell therapies for treating recurrent ER-positive metastatic breast cancer. The study found that these inhibitors cause breast tumors to secrete chemokines that attract T cells, improving patients' response to cancer immunotherapies.
A UMass Amherst research team has engineered a nanoparticle that can deliver cancer-fighting drugs to specific cells, reducing side effects. The innovation combines biologics and antibody-drug conjugates, enabling safer treatments for various genetic diseases.
A patient support program for people with autoimmune diseases and complex medication regimens can help them avoid using opioids or reduce their use. The study found that patients in the program were 13% less likely to start taking opioid pain medications and 26% less likely to fill two or more opioid prescriptions.
Researchers found that tumors can take up significant amounts of nanoparticle albumin-bound paclitaxel and that manipulating signaling pathways involved in nutrient uptake can enhance its consumption, boosting treatment efficacy
A team of researchers led by Lehigh University's Damien Thévenin is studying the connections between a protein called PTPRJ and human health. They aim to develop therapies that could overcome resistance to current treatments and provide new hope for cancer patients.
A Yale-led study found that new medicines and vaccines approved for use in the US are often not accessible in countries where they were developed, highlighting gaps in access to new medications. The study suggests that governments of host countries should require pharmaceutical companies to commit to submitting marketing approval appli...
A recent study analyzing 156,570 hospitalized patients found that anti-infective agents, cancer medications, and nonsteroidal anti-inflammatory drugs were the most toxic to the liver. Voriconazole, an antifungal medication, was associated with the highest incidence of drug-induced liver injury.
Researchers at Federal University of Rio de Janeiro discover a crucial link between phase transition and cancer pathology. Mutant p53 aggregates are formed through liquid-to-liquid phase separation, progressing to a gel-like or solid-like state that plays a key role in cancer development.
A new study by UCLA researchers identified a novel combination therapy using immune checkpoint inhibitors with ATRA to potentially overcome resistance to immunotherapy in LKB1-deficient lung cancer. The therapy led to eradication of over 70% of tumors and generated durable tumor-specific immunity.
A new study published in Blood Advances has identified a gene variant, mesothelin (MSLN), that is abnormally expressed in more than one-third of childhood and young adult AML cases. This discovery could lead to the development of precision medicine treatments for children with AML.
A UCLA team discovered a molecule that allows cancer stem cells to bypass the immune system, leading to increased growth and spread of head and neck squamous cell cancers. Inhibiting this molecule has been shown to disrupt cancer progression and eliminate these stem cells.
Researchers are testing cognitive behavioral therapy called Memory and Attention Adaptation Training (MAAT) to improve memory problems and emotional resilience among breast cancer survivors. The study aims to evaluate the effects of MAAT and supportive therapy on cognitive dysfunction after chemotherapy.
Researchers discovered that deleting the aryl hydrocarbon receptor from oral cancer cells results in a robust tumor-specific immune response, allowing mice to reject the cancer. This finding provides a new target for cancer immunotherapy treatment, potentially leading to more effective treatments.
A computational method using machine learning and feature sets derived from molecular simulation can predict the functional consequences of genetic variation in cancer drugs. This technology has the potential to accurately diagnose cancer variants and improve treatment outcomes by tailoring therapy to individual genetic profiles.
University of East Anglia researchers develop a new method for 3D printing medicine in highly porous structures, allowing for tailored drug release rates and improved patient outcomes. The technology has the potential to produce customized pills with accurate doses and reduced side effects.
A study published in Nature Communications found that rucaparib is effective in treating ovarian cancers with inherited or somatic mutations in DNA repair genes. The drug targets the Achilles heel of cancers with defects in DNA repair, outperforming chemotherapy in early treatment stages.
Merck Animal Health donates $100,000 to Morris Animal Foundation for animal cancer studies, doubling impact through the Stop Cancer Furever campaign. The funding supports groundbreaking research aimed at treating and preventing cancers in companion animals.
New research reveals patients with multiple comorbidities are more likely to be screened for colorectal cancer than those without any health conditions. Regular screenings significantly reduce cancer mortality.
Researchers have discovered that nanoparticles containing chemotherapy drug Capecitabine can attach to diseased cells, bypassing healthy ones and reducing toxic side effects. This targeted delivery system has shown promising results in animal experiments, improving cancer treatment outcomes.
The Digital Display Precision Predictor (DDPP) is a global biomarker model that predicts the duration of progression-free survival for cancer patients undergoing targeted therapy. It provides insight into the status of activation of almost all drug targets in tumor progression, enabling optimal treatment selection.
Researchers developed a topical cream using BRAF inhibitor LUT014 to reduce skin rash caused by EGFR inhibitors in colorectal cancer patients. The study showed that the treatment improved skin condition and reduced severity of the rash in 6 out of 10 patients.
Researchers discovered that targeting androgen receptors can destroy bladder cancer cells. The study found a common protein variant in malignant bladder tumor cells, which could lead to new therapeutic strategies.
A new study from the University of Missouri School of Medicine found that people of color, those with a higher income, and younger individuals are more likely to participate in cancer clinical trials. The analysis of 20,053 respondents showed an average overall clinical trial participation rate of 6.51%, with significant differences in...
A combination of inexpensive oral medications may treat fatigue-inducing anemias, a new discovery suggests. The therapy targets the root cause of anemia: disrupted cellular organelles, specifically the Golgi apparatus.
Researchers identified DUSP16 as a protein that promotes chemotherapy resistance in four types of cancer. Elevated DUSP16 levels can lead to reduced treatment effectiveness, highlighting its potential use as a biomarker for sensitivity to chemotherapy.
Scientists have developed a new class of cancer drug targeting enzymes that play a key role in translating DNA into proteins. This approach shows promising results in treating acute myeloid leukaemia, with the drug significantly reducing cancer cell growth and proliferation.
Recent studies at VCU Massey Cancer Center discovered a link between prolactin and breast cancer development. The hormone was found to act as a major contributor to breast cancer growth and could inform the creation of targeted drugs to treat multiple forms of the disease.
A new study published in Diagnostics demonstrates that artesunate, a drug synthesized from Artemisia annua, kills ovarian cancer cells. The researchers found anticancer activity at achievable concentrations, supporting the clinical development of this strategy.
Researchers at Ohio State University Comprehensive Cancer Center identified distinct mutational and molecular changes in four SCLC subtypes, providing new insights into treatment resistance. The findings suggest that subtyping patients before systemic therapy could play a role in drug development and therapy selection.
Dr. David Lyden, a Weill Cornell Medicine physician-scientist, has been inducted into the Association of American Physicians for his pioneering work on cancer metastasis and spread. His research reveals that tumors produce factors that prime distant organs to become hospitable sites for cancer growth.
A new analysis published in Psycho-Oncology found that fear of cancer recurrence leads to increased use of healthcare resources by cancer survivors. Implementing existing effective interventions for fear of cancer recurrence may improve both mental health and reduce unnecessary healthcare usage.